Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ruth Pettengell, Antonio Salar Silvestre, Matthias Schwenkglenks, Francesca Gaia Rossi, Ulrich Duehrsen, Gregor Verhoef, Pieternella Johanna Lugtenburg, Tracey Wheeler, Beatriz Pujol & Corinne Haioun. (2013) Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R)CHOP. Hematology 18:1, pages 26-29.
Read now
Read now
Marie-Hélène Lafeuille, Robert A. Bailey, Francis Vekeman, R. Scott McKenzie & Patrick Lefebvre. (2012) Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings. Journal of Medical Economics 15:2, pages 352-360.
Read now
Read now
Corinne Haioun, Antonio Salar, Ruth Pettengell, Hans Erik Johnsen, Ulrich Duehrsen, Francesca Gaia Rossi, Gregor Verhoef, Matthias Schwenkglenks, Ulrich Jaeger, Lisa Hamilton, Beatriz Pujol & Pieternella Johanna Lugtenburg. (2011) Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study. Leukemia & Lymphoma 52:5, pages 796-803.
Read now
Read now
Francis Vekeman, R. Scott McKenzie, Brahim K. Bookhart, François Laliberté, Mei Sheng Duh, Catherine Tak Piech & Patrick Lefebvre. (2009) Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database. Journal of Medical Economics 12:1, pages 1-8.
Read now
Read now
Patrick Lefebvre, Antoine Gosselin, R. Scott McKenzie, Samir H. Mody, Catherine Tak Piech & Mei Sheng Duh. (2006) Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Current Medical Research and Opinion 22:9, pages 1623-1631.
Read now
Read now
David H. Henry, Lucio N. Gordan, Veena Charu, Francois E. Wilhelm, Denise Williams, John Xie & Richard C. Woodman. (2006) Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Current Medical Research and Opinion 22:7, pages 1403-1413.
Read now
Read now
Articles from other publishers (12)
Paul Cornes & Matti Aapro. (2018) The Impact of Biosimilars in Supportive Care in Cancer. European Oncology & Haematology 14:1, pages 20.
Crossref
Crossref
R. Ravasio, G. Bernardo, C. Cerra & P. Fratino. (2013) Analisi di minimizzazione dei costi degli agenti stimolanti l’eritropoiesi nel trattamento dell’anemia indotta da chemioterapiaCost minimization analysis of erythropoietin receptor agonists in the treatment of cancer patients with anemia. PharmacoEconomics Italian Research Articles 11:1, pages 15-23.
Crossref
Crossref
John A. Glaspy, Veena Charu, Donghan Luo, Victor Moyo, Marc Kamin & Francois E. Wilhelm. (2009) Initiation of epoetin-α therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy. Cancer 115:5, pages 1121-1131.
Crossref
Crossref
José Luis Pontón Sivillá, Evaristo Feliu Frasnedo, Pilar Modamio Charles, Eduardo L. Mariño Hernández, Albert Font Pous, Clara Lezcano Rubio, José María Ribera Santasusana & Xavier Bonafont Pujol. (2008) Estudio de la efectividad de tres esquemas de administración de factores estimuladores de la eritropoyesis en pacientes con anemia asociada a quimioterapia por una neoplasia sólida o hematologica. Medicina Clínica 131:12, pages 447-451.
Crossref
Crossref
David H. Henry. (2008) Extended-dosing epoetin alfa for chemotherapy-induced anemia: focus on elderly breast and colorectal cancer patients. Community Oncology 5:6, pages 310-321.
Crossref
Crossref
Mei Sheng Duh, Jennifer R Weiner, Leigh Ann White, Patrick Lefebvre & Paul E Greenberg. (2008) Management of Anaemia. PharmacoEconomics 26:2, pages 99-120.
Crossref
Crossref
Bonne Biesma, Paul R. van de Werf, Christian F. Melissant & Ronald G.P.M. Brok. (2007) Anaemia management with epoetin alfa in lung cancer patients in The Netherlands. Lung Cancer 58:1, pages 104-111.
Crossref
Crossref
Francis VekemanR. Scott McKenzie, Patrick Lefebvre, Sue H. Watson, Samir H. Mody, Catherine Tak Piech & Mei Sheng Duh. (2007) Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. American Journal of Health-System Pharmacy 64:18, pages 1943-1949.
Crossref
Crossref
David Jaspan. (2007) Erythropoietic therapy: Cost efficiency and reimbursement. American Journal of Health-System Pharmacy 64:16_Supplement_11, pages S19-S29.
Crossref
Crossref
David H. Henry. (2007) Epoetin Alfa Treatment for Patients with Chemotherapy-Induced Anemia. Supportive Cancer Therapy 4:2, pages 78-91.
Crossref
Crossref
Antoine Gosselin, Chris L. Pashos, Carolyn Harley, Tami L. Mark & R. Scott McKenzie. (2006) Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: An analysis of four observational studies. Clinical Therapeutics 28:10, pages 1701-1708.
Crossref
Crossref
Mei Sheng Duh, Samir H. Mody, R. Scott McKenzie, Patrick Lefebvre, Antoine Gosselin & Catherine Tak Piech. (2006) Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Clinical Therapeutics 28:9, pages 1443-1450.
Crossref
Crossref